Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $600
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Stephen Baxter has maintained an Overweight rating on Elevance Health (NYSE:ELV) and increased the price target from $557 to $600.
April 19, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Stephen Baxter reaffirmed an Overweight rating on Elevance Health and raised the price target to $600 from $557.
The increase in the price target by a reputable analyst like Stephen Baxter suggests a strong confidence in Elevance Health's future performance. This endorsement is likely to positively influence investor sentiment and the stock's short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100